2020 ASCO Virtual Direct™ Highlights

 

Lung
06:34

2020 ASCO Virtual Direct™ Highlights

FDA Approved Pralsetinib (BLU-667) in RET+ mNSCLC: ARROW Trial Overview

FEATURING Michael Shafique
  • 27 views
  • April 13, 2021
05:39

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on ctDNA: Can We Use ctDNA as a Marker of MRD Following Definitive Treatment in Localized NSCLC? Is the Absence of Detectable BRAFV600 ctDNA at Baseline Associated With Improved PFS and OS in Pts Receiving Dabrafenib and Trametinib?

FEATURING Martin Dietrich
  • 117 views
  • November 11, 2020
15:28

2020 ASCO Virtual Direct™ Highlights

Update on ctDNA in NSCLC: Does ctDNA Predict Post-Therapy PFS & OS? How May NGS of cfDNA Help Provide Prognostic Information for ALK-Rearranged Disease?

FEATURING Martin Dietrich
  • 236 views
  • November 11, 2020
16:48

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on Stage 3 EGFR+ NSCLC: Should Osimertinib Be Considered for Patients With EGFR Exon 21 Mutation in Adjuvant Setting?

FEATURING John Vu
  • 220 views
  • September 28, 2020
  • 2
15:13

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Updates on IO in ES-SCLC: Should You Recommend 1L IO+EP Combination Instead of EP Alone?

FEATURING John Vu
  • 70 views
  • September 28, 2020
13:19

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on 1L mNSCLC: Nivo + Ipi + 2 Cycles Chemo vs. 4 Cycles Chemo - How Does This Impact 1L Treatment of Non-Driver Mutated NSCLC?

FEATURING Michael Shafique
  • 109 views
  • September 25, 2020
  • 1
11:33

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on mNSCLC: Will the Efficacy of T-DXd in HER2+ Disease Add HER2 Mutation to the List of Essential NSCLC Biomarkers? OS With Bevacizumab + Erlotinib in EGFR+ NSCLC - Does It Change the Role of Osimertinib in 1L Therapy?

FEATURING Michael Shafique
  • 80 views
  • September 25, 2020